Publishers

Need unique free news content for your site customized to your audience?

Let's Discuss

PRESS RELEASE
By: News Direct
May 30, 2024

Tryptamine Therapeutics launches on ASX with innovative psilocin formulation

Tryptamine Therapeutics Inc. (ASX: TYP) CEO Jason Carroll sits down with Jonathan Jackson in the proactive studio to talk about the start of trading on the Australian Securities Exchange (ASX). Tryptamine, a clinical-stage biotechnology company, is focused on developing an intravenous-infused psilocin formulation for psychedelic-assisted therapy. The company’s core programs include TRP-8803 (IV-infused psilocin formulation) and TRP-8802 (oral psilocybin). TRP-8803 aims to address the limitations of oral psilocybin, offering a faster onset of the psychedelic state, precise control of the experience, and a shorter duration, making it commercially viable. Three open-label trials in the United States using TRP-8802 for fibromyalgia, irritable bowel syndrome (IBS), and binge eating disorder (BED) are underway or recently completed. In a BED study at the University of Florida, TRP-8802 showed over 80% reduction in binge eating episodes and decreased anxiety and depression scores. Tryptamine Therapeutics is supported by a qualified Board, a Scientific Advisory Board, and partnerships with research organisations in the US and Australia. A world-first clinical trial of TRP-8803 will commence in Australia this quarter, with more trials planned for 2024 and 2025.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/tryptamine-therapeutics-launches-on-asx-with-innovative-psilocin-formulation-416576979

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This press release is distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Tryptamine Therapeutics launches on ASX with innovative psilocin formulation.

{site_meta && site_meta.display_name} Logo

News Direct

The News Direct platform offers a unique blend of technology and customization. Dive into a world of intuitive design, featuring compelling visuals, interactive elements, and seamless navigation.